Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | USP8 | P40818 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | STAT5B | P51692 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29929823 | 1.00 | EGLN2 (0.42) | EGLN2CYP11B1CYP11B2ALDH1A1KDM4E | |
| SCHEMBL384105 | 0.78 | KEAP1 (0.38) | EGLN2CYP11B1CYP11B2ALDH1A1KDM4E | |
| SCHEMBL16321670 | 0.78 | ALDH1A1 (0.44) | EGLN2CYP11B1CYP11B2ALDH1A1KDM4E | |
| SCHEMBL1976471 | 0.78 | ABL1 (0.35) | EGLN2CYP11B1CYP11B2ALDH1A1KDM4E | |
| SCHEMBL30834616 | 0.78 | PIK3CD (0.51) | EGLN2CYP11B1CYP11B2ALDH1A1KDM4E | |
| SCHEMBL18109302 | 0.78 | PIK3CD (0.51) | EGLN2CYP11B1CYP11B2ALDH1A1KDM4E | |
| SCHEMBL10325957 | 0.78 | AGBL2 (0.41) | EGLN2CYP11B1CYP11B2ALDH1A1KDM4E | |
| SCHEMBL12721108 | 0.78 | EGLN2 (0.40) | EGLN2CYP11B1CYP11B2ALDH1A1KDM4E | |
| SCHEMBL16769277 | 0.78 | CYP11B1 (0.40) | EGLN2CYP11B1CYP11B2ALDH1A1KDM4E | |
| SCHEMBL2298550 | 0.78 | EGLN2 (0.40) | EGLN2CYP11B1CYP11B2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117199519-A | Electrolyte, preparation method and application thereof, and lithium battery | 北京纳米能源与系统研究所 | 2023-12-08 | — | — | CN | claimed |
| CN-114984928-A | Modified porous cyclodextrin polymer material and preparation method and application thereof | 中南大学 | 2022-09-02 | — | — | CN | claimed |
| CN-112300793-A | Preparation method of pure organic phosphorescent material based on bis-carbazole pyridine derivative | 北京化工大学 | 2021-02-02 | — | — | CN | claimed |
| EP-2069325-A2 | ISOQUINOLINE, QUINAZOLINE AND PHTHALAZINE DERIVATIVES | Serenex, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | ESANEX, INC. | 2008-03-20 | — | — | US | claimed |
| WO-2008024977-A2 | ISOQUINOLINE, QUINAZOLINE AND PHTHALAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| EP-4698520-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | Gandeeva Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4688155-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | Bial-Portela & CA, S.A. (PT) | 2026-02-11 | — | — | EP | disclosed |
| EP-4655284-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-12-03 | — | — | EP | disclosed |
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025093624-A1 | A PROCESS FOR PREPARING 3,5-DIFLUORO-2-PYRIDINECARBOXAMIDE | INTERVET INTERNATIONAL B.V. (NL) | 2025-05-08 | — | — | WO | disclosed |
| US-20250051347-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals, Inc. (CN) | 2025-02-13 | — | — | US | disclosed |
| WO-2025023852-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | disclosed |
| WO-2001068640-A1 | MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068641-A1 | 6-AMINOALKYL-DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068642-A1 | DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068647-A1 | MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| EP-1080086-A1 | DIHYDROPYRIMIDINES | BAYER AG (DE) | 2001-03-07 | — | — | EP | disclosed |
| WO-2000058302-A1 | DIHYDROPYRIMIDINES AND THEIR USE IN THE TREATMENT OF HEPATITIS B | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-05 | — | — | WO | disclosed |
| WO-1999054326-A1 | DIHYDROPYRIMIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | H1-5, NDUFS5, IL5 | EGLN2 1843/4885CYP11B1 944/4885CYP11B2 921/4885 |
| US-20250051347-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | AR, ADRM1, MDM2 | EGLN2 4585/4885CYP11B1 194/4885CYP11B2 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.